Portfolio Companies – Page 25 – BioScience Managers

AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus

3rd August 2016/in Portfolio Companies

Wednesday, August 3, 2016 8:45 am EDT SAN DIEGO–(BUSINESS WIRE)–Link here. AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has completed enrollment of its Phase 1 clinical trial to evaluate the safety of AB-SA01, its proprietary phage cocktail targeting Staphylococcus aureus (S. […]

Nexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference

20th July 2016/in Portfolio Companies

DUBLIN, Ireland, July 20, 2016 (GLOBE NEWSWIRE) –Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of Veterinary Internal Medicine (JVIM), as well as an upcoming presentation Nexvet’s Chief Scientific Officer Dr. David Gearing at the Veterinary Pain Short […]

SeaDragon appoints new Chief Executive

18th July 2016/in Portfolio Companies, SeaDragon

NZX / MEDIA RELEASE 18 July 2016. Link here. SeaDragon appoints new Chief Executive Dr Nevin Amos to take the reins of the company in October 2016. SeaDragon Board thanks outgoing Interim Chief Executive Richard Alderton for leadership through the company’s transition to Omega-3 fish oil markets SeaDragon, New Zealand’s largest refiner and blender of […]

Saluda Medical featured in Nature Journal

14th July 2016/in Portfolio Companies, Saluda Medical

Biomedicine: Move over, morphine James Mitchell Crow Nature 535, S4–S6 (14 July 2016) Published online 13 July 2016 Link here.

Avita Medical announces Rights Issue raises $9 million

11th July 2016/in Portfolio Companies

Northridge, CA, Perth, Australia and London, United Kingdom – 11 July 2016 Avita Medical Ltd today announced a partially underwritten non-renounceable rights issue to raise up to approximately $11m (Rights Issue) to support the Company’s strategy to launch in the US and push forward with product commercialization. Link here.

Avita Medical scoops One Nucleus Summer BioNewsRound Award 2016

29th June 2016/in Portfolio Companies

Northridge, CA, Perth, Australia and London, United Kingdom – 29 June 2016 Link here.

Avita Medical Awarded US$7.96m in BARDA Extension Deal

27th June 2016/in Portfolio Companies

Northridge, CA, Perth, Australia and London, United Kingdom – 27 June 2016 Link here.

Nexvet Presents Expanded Positive Clinical Data for Ranevetmab (NV-01) and Frunevetmab (NV-02) at ACVIM

9th June 2016/in Portfolio Companies

DUBLIN, Ireland, June 09, 2016 (GLOBE NEWSWIRE)- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, is today presenting expanded results regarding completed clinical studies for ranevetmab (or “NV-01”) and frunevetmab (or “NV-02”) to veterinarians and veterinary key opinion leaders at a Nexvet-hosted seminar at the American College of Veterinary Internal Medicine (ACVIM) Forum today in […]

Nexvet Announces Opening of Manufacturing Facility and Production Milestone Achievement

3rd June 2016/in Portfolio Companies

DUBLIN, Ireland, June 03, 2016 (GLOBE NEWSWIRE) – Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics developer, today announced the official opening of BioNua Limited, its veterinary biologics manufacturing facility in Tullamore, Ireland, as well as in-house production of its first clinical trial batch of NV-02 from a 200 liter production bioreactor. NV-02 is Nexvet’s monoclonal […]